MedPath

Pharmosa Biopharm Inc.

🇹🇼Taiwan
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:2

Trial Phases

1 Phases

Phase 1:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (100.0%)

Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults

Phase 1
Recruiting
Conditions
Pulmonary Arterial Hypertension
Interventions
First Posted Date
2024-05-28
Last Posted Date
2025-06-04
Lead Sponsor
Pharmosa Biopharm Inc.
Target Recruit Count
56
Registration Number
NCT06429930
Locations
🇳🇿

NZCR Ltd (New Zealand Clinical Research), Christchurch, New Zealand

Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults

Phase 1
Completed
Conditions
Pulmonary Arterial Hypertension
Interventions
Drug: L608 Inhalation Solution
Drug: Placebo solution
First Posted Date
2023-07-11
Last Posted Date
2024-10-16
Lead Sponsor
Pharmosa Biopharm Inc.
Target Recruit Count
64
Registration Number
NCT05938946
Locations
🇦🇺

CMAX Clinical Research Pty Ltd, Adelaide, South Australia, Australia

Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606

Phase 1
Completed
Conditions
Pulmonary Arterial Hypertension
Interventions
Drug: L606 (Liposomal Treprostinil) Inhalation Solution 51ug
Device: L606 Inhalation System
Other: Placebo Solution
First Posted Date
2019-08-01
Last Posted Date
2020-12-22
Lead Sponsor
Pharmosa Biopharm Inc.
Target Recruit Count
52
Registration Number
NCT04041648
Locations
🇺🇸

PPD, Austin, Texas, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.